3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
437
Breast Neoplasms
382
Neoplasms
291
Prostatic Neoplasms
195
Neoplasm Metastasis
155
Multiple Myeloma
148
Colorectal Neoplasms
124
Lung Neoplasms
105
Ovarian Neoplasms
102
Parkinson Disease 4, Autosomal Dominant Lewy Body
98
Melanoma
95
Lymphoma, Follicular
94
Recurrence
89
Lymphoma, Non-Hodgkin
82
Papillomavirus Infections
81
Leukemia, Lymphocytic, Chronic, B-Cell
81
Carcinoma, Hepatocellular
81
Stomach Neoplasms
76
Small Cell Lung Carcinoma
73
Leukemia, Myeloid, Acute
70
Pancreatic Neoplasms
67
Pain
66
Carcinoma, Renal Cell
65
Uterine Cervical Neoplasms
64
Keratosis, Actinic
63
Urinary Bladder Neoplasms
59
Lymphoma, Large B-Cell, Diffuse
53
Myasthenia Gravis
52
Leiomyoma
49
Carcinoma
49
Interventions
Adalimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
INDUSTRY
×
Hidradenitis Suppurativa
×
Clear all
NCT01635764
2018-01-24
PIONEER (OLE)
AbbVie
Phase 3
Completed
508 enrolled
9 charts